Ectonucleotidase inhibitors: a patent review (2011-2016)

References

• Fredholm BB, IJzerman AP, Jacobson KA, et al. International union of pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev. 2001;53:527–552.
   PubMed Web of Science ®Google Scholar
• Long X, Mokelke EA, Neeb ZP, et al. Adenosine receptor regulation of coronary blood flow in Ossabaw miniature swine. J Pharmacol Exp Ther. 2010;335:781–787.
   PubMed Web of Science ®Google Scholar
• Jacobson KA, Gao Z-G. Adenosine receptors as therapeutic targets. Nat Rev Drug Discov. 2006;5:247–264.
   PubMed Web of Science ®Google Scholar
• Cohen S, Barer F, Bar-Yehuda S, et al. A3 adenosine receptor allosteric modulator induces an anti-inflammatory effect: in vivo studies and molecular mechanism of action. Mediators Inflamm. 2014;2014:1–9.
   Web of Science ®Google Scholar
• Akkari R, Burbiel JC, Hockemeyer J, et al. Recent progress in the development of adenosine receptor ligands as antiinflammatory drugs. Curr Top Med Chem. 2006;6:1375–1399.
   PubMed Web of Science ®Google Scholar
• Yang D, Zhang Y, Nguyen HG, et al. The A 2B adenosine receptor protects against inflammation and excessive vascular adhesion. J Clin Invest. 2006;116:1913–1923.
   PubMed Web of Science ®Google Scholar
• Haskó G, Pacher P, Vizi ES, et al. Adenosine receptor signaling in the brain immune system. Trends Pharmacol Sci. 2005;26:511–516.
   PubMed Web of Science ®Google Scholar
• North RA. P2X receptors. Phil Trans R Soc B. 2016;371:20150427. .
   PubMed Web of Science ®Google Scholar
• Keystone EC, Wang MM, Layton M, et al. Clinical evaluation of the efficacy of the P2X7 purinergic receptor antagonist AZD9056 on the signs and symptoms of rheumatoid arthritis in patients with active disease despite treatment with methotrexate or sulphasalazine. Ann Rheum Dis. 2012;71:1630–1635. .
   PubMed Web of Science ®Google Scholar
• Xu B, Stephens A, Kirschenheuter G, et al. Acyclic analogues of adenosine bisphosphates as P2Y receptor antagonists: phosphate substitution leads to multiple pathways of inhibition of platelet aggregation. J Med Chem. 2002;45:5694–5709.
   PubMed Web of Science ®Google Scholar
• Fredholm BB, Abbracchio MP, Burnstock G, et al. Towards a revised nomenclature for P1 and P2 receptors. Trends Pharmacol Sci. 1997;18:79–82.
   PubMed Web of Science ®Google Scholar
• Di Virgilio F, Chiozzi P, Ferrari D, et al. Nucleotide receptors: an emerging family of regulatory molecules in blood cells. Blood. 2001;97:587–600.
   PubMed Web of Science ®Google Scholar
• Burnstock G, Williams M. P2 purinergic receptors: modulation of cell function and therapeutic potential. J Pharm Exp Ther. 2000;295:862–869.
   PubMed Web of Science ®Google Scholar
• Erb L, Weisman GA. Coupling of P2Y receptors to G proteins and other signaling pathways. Wiley Interdiscip Rev Membr Transp Signal. 2012;1:789–803.
   PubMedGoogle Scholar
• von Kügelgen I, Hoffmann K. Pharmacology and structure of P2Y receptors. Neuropharmacology. 2016;104:50–61.
   PubMed Web of Science ®Google Scholar
• Brunschweiger A, Müller CE. P2 receptors activated by uracil nucleotides-an update. Curr Med Chem. 2006;13:289–312.
   PubMed Web of Science ®Google Scholar
• Mansoor, S.E., Lu, W., Oosterheert, W., Shekhar, M., Tajkhorshid, E., Gouaux, E. X-ray structures define human P2X3 receptor gating cycle and antagonist action. Nature. 2016;538:66–71.
   Google Scholar
• Zhang D, Gao Z-G, Zhang K, et al. Two disparate ligand-binding sites in the human P2Y1 receptor. Nature. 2015;520:317–321.
   PubMed Web of Science ®Google Scholar
• Zhang J, Zhang K, Gao Z-G, et al. Agonist-bound structure of the human P2Y12 receptor. Nature. 2014;509:119–122.
   PubMed Web of Science ®Google Scholar
• Robson SC, Sévigny J, Zimmermann H. The E-NTPDase family of ectonucleotidases: structure function relationships and pathophysiological significance. Purinergic Signal. 2006;2:409.
   PubMedGoogle Scholar
• Atkinson B, Dwyer K, Enjyoji K, et al. Ecto-nucleotidases of the CD39/NTPDase family modulate platelet activation and thrombus formation: potential as therapeutic targets. Blood Cells Mol Dis. 2006;36:217–222.
   PubMed Web of Science ®Google Scholar
• Kirley TL, Crawford PA, Smith TM. The structure of the nucleoside triphosphate diphosphohydrolases (NTPDases) as revealed by mutagenic and computational modeling analyses. Purinergic Signal. 2006;2:379. .
   PubMedGoogle Scholar
• Goding JW, Grobben B, Slegers H. Physiological and pathophysiological functions of the ecto-nucleotide pyrophosphatase/phosphodiesterase family. Biochim Biophys Acta. 2003;1638:1–19.
   PubMed Web of Science ®Google Scholar
• Bollen M, Gijsbers R, Ceulemans H, et al. Nucleotide pyrophosphatases/phosphodiesterases on the move. Crit Rev Biochem Mol Biol. 2000;35:393–432.
   PubMed Web of Science ®Google Scholar
• Al-Rashida M, Iqbal J. Inhibition of alkaline phosphatase: an emerging new drug target. Mini Rev Med Chem. 2015;15:41–51.
   PubMed Web of Science ®Google Scholar
• Millán JL. Alkaline phosphatases structure, substrate specificity and functional relatedness to other members of a large superfamily of enzymes. Purinergic Signal. 2006;2:335–341.
   PubMedGoogle Scholar
• M-H LD, Millán JL. Structural evidence of functional divergence in human alkaline phosphatases. J Biol Chem. 2002;277:49808–49814.
   PubMed Web of Science ®Google Scholar
• Stec B, Cheltsov A, Millán JL. Refined structures of placental alkaline phosphatase show a consistent pattern of interactions at the peripheral site. Acta Crystallogr Sect F Struct Biol Cryst Commun. 2010;66:866–870.
   PubMedGoogle Scholar
• Llinas P, Masella M, Stigbrand T, et al. Structural studies of human alkaline phosphatase in complex with strontium: implication for its secondary effect in bones. Protein Sci. 2006;15:1691–1700.
   PubMed Web of Science ®Google Scholar
• Llinas P, Stura EA, Ménez A, et al. Structural studies of human placental alkaline phosphatase in complex with functional ligands. J Mol Biol. 2005;350:441–451.
   PubMed Web of Science ®Google Scholar
• Zebisch M, Krauss M, Schäfer P, et al. Crystallographic snapshots along the reaction pathway of nucleoside triphosphate diphosphohydrolases. Structure. 2013;21:1460–1475.
   PubMed Web of Science ®Google Scholar
• Zebisch M, Baqi Y, Schäfer P, et al. Crystal structure of NTPDase2 in complex with the sulfoanthraquinone inhibitor PSB-071. J Struct Biol. 2014;185:336–341.
   PubMed Web of Science ®Google Scholar
• Zebisch M, Krauss M, Schäfer P, et al. Crystallographic evidence for a domain motion in rat nucleoside triphosphate diphosphohydrolase (NTPDase) 1. J Mol Biol. 2012;415:288–306.
   PubMed Web of Science ®Google Scholar
• Zebisch M, Sträter N. Structural insight into signal conversion and inactivation by NTPDase2 in purinergic signaling. Proc Natl Acad Sci. 2008;105:6882–6887.
   PubMed Web of Science ®Google Scholar
• Albright RA, Ornstein DL, Cao W, et al. Molecular basis of purinergic signal metabolism by ectonucleotide pyrophosphatase/phosphodiesterases 4 and 1 and implications in stroke. J Biol Chem. 2014;289:3294–3306.
   PubMed Web of Science ®Google Scholar
• Bain G, Shannon KE, Huang F, et al. Selective inhibition of autotaxin is efficacious in mouse models of liver fibrosis. J Pharm Exp Ther. 2017;360:1–13.
   PubMed Web of Science ®Google Scholar
• Stein AJ, Bain G, Prodanovich P, et al. Structural basis for inhibition of human autotaxin by four potent compounds with distinct modes of binding. Mol Pharmacol. 2015;88:982–992.
   PubMed Web of Science ®Google Scholar
• Gorelik A, Liu F, Illes K, et al. Crystal structure of the human alkaline sphingomyelinase provides insights into substrate recognition. J Biol Chem. 2017;292:7087–7094.
   PubMed Web of Science ®Google Scholar
• Knapp K, Zebisch M, Pippel J, et al. Crystal structure of the human ecto-5′-nucleotidase (CD73): insights into the regulation of purinergic signaling. Structure. 2012;20:2161–2173.
   PubMed Web of Science ®Google Scholar
• Heuts DP, Weissenborn MJ, Olkhov RV, et al. Crystal structure of a soluble form of human CD73 with Ecto‐5′‐nucleotidase activity. Chem Bio Chem. 2012;13:2384–2391.
   Google Scholar
• Müller CE, Brunschweiger A, Iqbal J, Ectonucleotidase inhibitors patent US20100204182. 2010.
   Google Scholar
• al-Rashida M, Iqbal J. Therapeutic potentials of ecto‐nucleoside triphosphate diphosphohydrolase, ecto-nucleotide pyrophosphatase/phosphodiesterase, ecto-5′-nucleotidase, and alkaline phosphatase inhibitors. Med Res Rev. 2014;34:703–743. .
   PubMed Web of Science ®Google Scholar
• Zimmermann H Ecto-nucleotidases. Purinergic and Pyrimidinergic Signalling I: Springer; 2001. p. 209–250.
   Google Scholar
• Brunschweiger A, Iqbal J, Umbach F, et al. Selective nucleoside triphosphate diphosphohydrolase-2 (NTPDase2) inhibitors: nucleotide mimetics derived from uridine-5′-carboxamide. J Med Chem. 2008;51:4518–4528.
   PubMed Web of Science ®Google Scholar
• Bhattarai S, Freundlieb M, Pippel J, et al. α, β-methylene-ADP (AOPCP) derivatives and analogues: development of potent and selective ecto-5′-nucleotidase (CD73) inhibitors. J Med Chem. 2015;58:6248–6263.
   PubMed Web of Science ®Google Scholar
• de Mendonça A, Ribeiro J. Endogenous adenosine modulates long-term potentiation in the hippocampus. Neuroscience. 1994;62:385–390.
   PubMed Web of Science ®Google Scholar
• de Mendonca A, Almeida T, Bashir Z, et al. Endogenous adenosine attenuates long-term depression and depotentiation in the CA1 region of the rat hippocampus. Neuropharmacology. 1997;36:161–167.
   PubMed Web of Science ®Google Scholar
• Sebastiao AM, de Mendonca A, Moreira T, et al. Activation of synaptic NMDA receptors by action potential-dependent release of transmitter during hypoxia impairs recovery of synaptic transmission on reoxygenation. J Neurosci. 2001;21:8564–8571.
   PubMed Web of Science ®Google Scholar
• Stone TW, Collis MG, Williams M, et al. Adenosine: some therapeutic applications and prospects. Pharmacological sciences: perspectives for research and therapy in the late 1990s: Springer; 1995. p. 303–309.
   Google Scholar
• Zakharenko SS, Blundon JA, Method for improving learning patent WO2016134091. 2016.
   Google Scholar
• Mathieu P Ectonucleotidase pyrophosphate/phosphodiesterase-1 (enpp-1) as a target for the treatment of aortic valve stenosis and cardiovascular calcification. Google Patents; 2011.
   Google Scholar
• Mathieu P, Ectonucleotidase pyrophosphate/phosphodiestrase-1 (ENPP-1) as a target for the treatment of aortic valve stenosis and cardiovascular calcification patent US8435964. 2013.
   Google Scholar
• Zylka MJ. Pain-relieving prospects for adenosine receptors and ectonucleotidases. Trends Mol Med. 2011;17:188–196.
   PubMed Web of Science ®Google Scholar
• Zhang B. CD73: a novel target for cancer immunotherapy. Cancer Res. 2010;70:6407–6411.
   PubMed Web of Science ®Google Scholar
• Resta R, Yamashita Y, Thompson LF. Ecto-enzyme and signaling functions of lymphocyte CD 7 3. Immunol Rev. 1998;161:95–109.
   PubMed Web of Science ®Google Scholar
• Allard B, Pommey S, Smyth MJ, et al. Targeting CD73 enhances the antitumor activity of anti-PD-1 and anti-CTLA-4 mAbs. Clin Cancer Res. 2013;19:5626–5635.
   PubMed Web of Science ®Google Scholar
• Zhang B. CD73 promotes tumor growth and metastasis. Oncoimmunology. 2012;1:67–70.
   PubMed Web of Science ®Google Scholar
• Ohta A, Ohta A, Madasu M, et al. A2A adenosine receptor may allow expansion of T cells lacking effector functions in extracellular adenosine-rich microenvironments. J Immunol. 2009;183:5487–5493.
   PubMed Web of Science ®Google Scholar
• Stagg J, Divisekera U, Duret H, et al. CD73-deficient mice have increased antitumor immunity and are resistant to experimental metastasis. Cancer Res. 2011;71:2892–2900.
   PubMed Web of Science ®Google Scholar
• Chanteux S, Paturel C, Perrot I, et al., Cd73 blockade patent WO2016131950. 2016.
   Google Scholar
• Perrot I, Paturel C, Gauthier L, Cd73 blockade patent WO2016055609. 2016.
   Google Scholar
• Lonberg N, Korman AJ, Barnhart BC, et al., Antibodies against cd73 and uses thereof patent US20160145350. 2016.
   Google Scholar
• Quintana FJ, Mascanfroni ID, Methods and compositions of treating autoimmune diseases patent US20160058792. 2016.
   Google Scholar
• Mascanfroni ID, Yeste A, Vieira SM, et al. Efroni S. IL-27 acts on DCs to suppress the T cell response and autoimmunity by inducing expression of the immunoregulatory molecule CD39. Nat Immunol. 2013;14:1054–1063.
   PubMed Web of Science ®Google Scholar
• Mizumoto N, Kumamoto T, Robson SC, et al. CD39 is the dominant Langerhans cell–associated ecto-NTPDase: modulatory roles in inflammation and immune responsiveness. Nat Med. 2002;8:358–365.
   PubMed Web of Science ®Google Scholar
• Ohta A, Sitkovsky M. The adenosinergic immunomodulatory drugs. Curr Opin Pharmacol. 2009;9:501–506.
   PubMed Web of Science ®Google Scholar
• Sun X, Wu Y, Gao W, et al. CD39/ENTPD1 expression by CD4+ Foxp3+ regulatory T cells promotes hepatic metastatic tumor growth in mice. Gastroenterology. 2010;139:1030–1040.
   PubMed Web of Science ®Google Scholar
• Allard B, Longhi MS, Robson SC, et al. The ectonucleotidases CD39 and CD73: novel checkpoint inhibitor targets. Immunol Rev. 2017;276:121–144.
   PubMed Web of Science ®Google Scholar
• Cividini F, Cros-Perrial E, Pesi R, et al. Cell proliferation and drug sensitivity of human glioblastoma cells are altered by the stable modulation of cytosolic 5′-nucleotidase II. Int J Biochem Cell Biol. 2015;65:222–229.
   PubMed Web of Science ®Google Scholar
• Petter Jordheim L, Chaloin L. Therapeutic perspectives for cN-II in cancer. Curr Med Chem. 2013;20:4292–4303.
   PubMed Web of Science ®Google Scholar
• Cividini F, Filoni DN, Pesi R, et al. IMP–GMP specific cytosolic 5′-nucleotidase regulates nucleotide pool and prodrug metabolism. Biochim Biophys Acta. 2015;1850:1354–1361.
   PubMed Web of Science ®Google Scholar
• Cividini F, Tozzi MG, Galli A, et al. Cytosolic 5ʹ-nucleotidase II interacts with the leucin rich repeat of NLR family member Ipaf. PLoS ONE. 2015;10:e0121525.
   PubMed Web of Science ®Google Scholar
• Chaloin L, Peyrottes S, Lionne C, et al., 5ʹ-nucleotidase inhibitors and therapeutic uses thereof patent WO2015049447. 2015.
   Google Scholar
• Chaloin L, Peyrottes S, Lionne C, et al., 5ʹ-nucleotidase inhibitors and therapeutic uses thereof patent US20160272643. 2016.
   Google Scholar
• Stone TW, Ceruti S, Abbracchio MP. Adenosine receptors and neurological disease: neuroprotection and neurodegeneration. Adenosine Recep Health Dis Springer. 2009;193:535–587.
   Google Scholar
• Chen J-F, Sonsalla PK, Pedata F, et al. Adenosine A 2A receptors and brain injury: broad spectrum of neuroprotection, multifaceted actions and “fine tuning” modulation. Prog Neurobiol. 2007;83:310–331.
   PubMed Web of Science ®Google Scholar
• Abbracchio MP, Cattabeni F. Brain adenosine receptors as targets for therapeutic intervention in neurodegenerative diseases. Ann N Y Acad Sci. 1999;890:79–92.
   PubMed Web of Science ®Google Scholar
• Narisawa S, Harmey D, Yadav MC, et al. Novel inhibitors of alkaline phosphatase suppress vascular smooth muscle cell calcification. J Bone Miner Res. 2007;22:1700–1710.
   PubMed Web of Science ®Google Scholar
• Terkeltaub R. Physiologic and pathologic functions of the NPP nucleotide pyrophosphatase/phosphodiesterase family focusing on NPP1 in calcification. Purinergic Signal. 2006;2:371–377.
   PubMedGoogle Scholar
• Johnson K, Terkeltaub R. Inorganic pyrophosphate (PPI) in pathologic calcification of articular cartilage. Front Biosci. 2005;10:988–997.
   PubMed Web of Science ®Google Scholar
• Shayhidin EE, Forcellini E, Boulanger MC, et al. Quinazoline-4-piperidine sulfamides are specific inhibitors of human NPP1 and prevent pathological mineralization of valve interstitial cells. Br J Pharmacol. 2015;172:4189–4199.
   PubMed Web of Science ®Google Scholar
• Lecka J, Ben-David G, Simhaev L, et al. Nonhydrolyzable ATP analogues as selective inhibitors of human NPP1: a combined computational/experimental study. J Med Chem. 2013;56:8308–8320.
   PubMed Web of Science ®Google Scholar
• Wang L, Zhou X, Zhou T, et al. Ecto-5′-nucleotidase promotes invasion, migration and adhesion of human breast cancer cells. J Cancer Res Clin Oncol. 2008;134:365–372.
   PubMed Web of Science ®Google Scholar
• Yu Y, Wang W, Song L, et al. Ecto-5ʹ-nucleotidase expression is associated with the progression of renal cell carcinoma. Oncol Lett. 2015;9:2485–2494.
   PubMed Web of Science ®Google Scholar
• Haskó G, Csóka B, Németh ZH, et al. A 2B adenosine receptors in immunity and inflammation. Trends Immunol. 2009;30:263–270.
   PubMed Web of Science ®Google Scholar
• Koeppen M, Eckle T, Eltzschig HK. Interplay of hypoxia and A2B adenosine receptors in tissue protection. Adv Pharmacol. 2011;61:145.
   PubMedGoogle Scholar
• Ohta A, Sitkovsky M. Extracellular adenosine-mediated modulation of regulatory T cells. Front Immunol. 2014;5:304.
   PubMed Web of Science ®Google Scholar
• Stagg J, Beavis PA, Divisekera U, et al. CD73-deficient mice are resistant to carcinogenesis. Cancer Res. 2012;72:2190–2196.
   PubMed Web of Science ®Google Scholar
• Beavis PA, Divisekera U, Paget C, et al. Blockade of A2A receptors potently suppresses the metastasis of CD73+ tumors. Proc Natl Acad Sci USA. 2013;110:14711–14716.
   PubMed Web of Science ®Google Scholar
• Hilchey SP, Kobie JJ, Cochran MR, et al. Human follicular lymphoma CD39+-infiltrating T cells contribute to adenosine-mediated T cell hyporesponsiveness. J Immunol. 2009;183:6157–6166.
   PubMed Web of Science ®Google Scholar
• Hausler S, Del Barrio IM, Diessner J, et al. Anti-CD39 and anti-CD73 antibodies A1 and 7G2 improve targeted therapy in ovarian cancer by blocking adenosine-dependent immune evasion. Am J Transl Res. 2014;6:129–139.
   PubMed Web of Science ®Google Scholar
• Hayes GM, Cairns B, Levashova Z, et al. CD39 is a promising therapeutic antibody target for the treatment of soft tissue sarcoma. Am J Transl Res. 2015;7:1181.
   PubMed Web of Science ®Google Scholar
• Munkonda MN, Pelletier J, Ivanenkov VV, et al. Characterization of a monoclonal antibody as the first specific inhibitor of human NTP diphosphohydrolase-3. Febs J. 2009;276:479–496.
   PubMed Web of Science ®Google Scholar
• Hay CM, Sult E, Huang Q, et al. Targeting CD73 in the tumor microenvironment with MEDI9447. Oncoimmunology. 2016;5:e1208875.
   PubMed Web of Science ®Google Scholar